Candesartan chemical structure
Find information on thousands of medical conditions and prescription drugs.

Candesartan

Candesartan (kan-de-SAR-tan) belongs to the class of medicines called angiotensin II receptor antagonists. It is used to treat high blood pressure (hypertension) and is marketed under the brand name Atacand® (alternative name: Ratacand®) by AstraZeneca. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled.

Candesartan works by blocking the action of a substance in the body that causes blood vessels to tighten. As a result, candesartan relaxes blood vessels. This lowers blood pressure.

Side-effects

By decreasing aldosterone levels, candesartan and related drugs may cause hyperkalemia (high potassium levels in the blood). Supplements containing potassium, which are sometimes taken by patients with high blood pressure, are discouraged.

Some people taking candesartan report dizziness (occurs in 1 out of every 25 persons), blurry vision, lightheadedness, a sore throat or a runny nose. More serious side effects can be fainting, decreased sexual ability, jaundice, severe nausea, fatigue and chest pain.

Contraindications

It is contraindicated in pregnancy, especially in the last six months, preexistent hyperkalemia and a history of drug reactions to other AT II inhibitors.

Read more at Wikipedia.org


[List your site here Free!]


Candesartan improves outcomes in chronic heart failure
From American Family Physician, 4/1/04 by Anne D. Walling

Although outcomes in patients with chronic heart failure (CHF) have improved recently because of the increasingly widespread use of beta blockers and angiotensin-converting enzyme (ACE) inhibitors, patients remain at increased risk of hospital admission and cardiovascular death. In addition, CHF is the main reason for hospital admission in older adults, and its significance is expected to increase as the population ages. In the search for improved therapies for CHF, angiotensin II type 1 receptor blockers (ARBs) could prove valuable, especially in patients who cannot tolerate ACE inhibitors. Pfeffer and colleagues reported the results of large international trials of the ARB candesartan in patients with CHF in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) study.

They studied adult patients at 618 sites in six countries who had symptomatic CHF of New York Heart Association (NYHA) class II to IV of at least four weeks' duration. Patients with limited two-year survival were excluded from the study. Exclusion criteria included the following conditions: elevated levels of serum potassium or creatinine; bilateral renal artery stenosis; hypotension; recent myocardial infarction (MI); cardiac surgery, or stroke; or use of an ARB within the previous two weeks. Eligible patients were assigned to different studies based on left-ventricular ejection fraction (LVEF) and experience with ACE inhibitors. Patients with LVEF greater than 40 percent formed the CHARM-Preserved group, while patients with 40 percent or lower LVEF who were being treated with an ACE inhibitor were assigned to the CHARM-Added group, and those with 40 percent or lower LVEF who were not receiving an ACE inhibitor because of previous intolerance were assigned to the CHARM-Alternative group.

All patients were assigned randomly to treatment with candesartan or placebo. Starting dosages of candesartan were 4 mg or 8 mg daily, and the dosage was increased as tolerated to a target dosage of 32 mg daily. Once the drug dosage had been titrated, patients were followed every four months for at least two years. Use of conventional CHF therapy continued during the study at the physicians' discretion. Although overall mortality was the primary outcome, other outcomes monitored included cardiovascular death, hospital admission for CHF, MI, stroke, cardiac revascularization procedure, and new-onset diabetes.

The 3,803 patients treated with candesartan and the 3,796 given placebo were comparable in all important respects. During the median 37.7 months of follow-up, 886 candesartan-treated patients (23 percent) and 945 placebo-treated patients (25 percent) died of any cause. This lower rate of mortality among patients treated with candesartan was attributable to fewer cardiovascular deaths (691 [18 percent] compared with 769 [20 percent] in the placebo group), particularly during the first year of treatment.

Hospital admissions for CHF were reduced significantly in candesartan-treated patients (1,454 compared with 2,010 placebo-treated patients) and significantly fewer candesartan-treated patients had two or more admissions for CHF (9 percent compared with 12 percent for placebo). The overall reduction in risk of death or hospital admission with candesartan treatment was similar in men and women and was equivalent in the 1,736 patients 75 years or older compared with the younger patients. Effectiveness also was similar in patients with LVEF above or below 40 percent, across all NYHA classes of CHF, and irrespective of the presence of diabetes. By six months, 63 percent of patients in the candesartan group had achieved the target dosage, but 11 percent had discontinued the medication compared with 7 percent of patients who had discontinued placebo. By the end of the study, 23 percent of candesartan-treated survivors and 19 percent of placebo-treated patients had discontinued the medication. Laboratory abnormalities were the most common reasons given for discontinuation.

The authors conclude that candesartan therapy is associated with a small but significant reduction in overall death and hospital admission in patients with CHF, regardless of previous treatment or ejection fraction.

ANNE D. WALLING, M.D.

Pfeffer MA, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet September 6, 2003; 362:759-66.

EDITOR'S NOTE: When The Lancet publishes four individual "fast-track" articles and a commentary (1) on the results of a single study, a major shift in therapy is underway. In addition to the above "overall" study, articles have been published on the subgroup of patients with preserved ventricular function, and two articles were published on subgroups with reduced ventricular function (one group intolerant of ACE inhibitors and one group tolerant). In all cases, significant but sometimes modest benefits were obtained, and adverse effects were documented. A summary of this rather overwhelming wealth of information concludes that over three years, ARB therapy prevented one death per 63 patients treated, one hospitalization per 23 patients treated, and one new case of diabetes per 71 patients treated. The author recommends adding ARBs to optimal current therapy (i.e., ACE inhibitors, beta blockers, possibly spironolactone) in patients with CHF who have ejection fractions of 40 percent or less. Use of ARBs also is recommended in patients with CHF who are intolerant of ACE inhibitors. In patients with CHF who have ejection fractions greater than 40 percent, the modest risk reduction must be considered against adverse effects, tolerability, and other factors on an individual basis.

Even the apparently small gains in these patients should not be disregarded. Heart disease is the most common cause of death in the United States, accounting for more than 700,000 deaths annually. With numbers of this magnitude, even a 1 to 2 percent reduction in the rates of death or hospital admission saves 7,000 to 14,000 lives and potentially makes meaningful savings in suffering and health care costs. Many more studies and much more information on these drugs and other treatments for CHF are anticipated as we continue to "fine tune" therapies for this diverse group of patients.--A.D.W.

REFERENCE

(1.) White HD. Candesartan and heart failure: the allure of CHARM [Commentary]. Lancet 2003;362:754-5.

COPYRIGHT 2004 American Academy of Family Physicians
COPYRIGHT 2004 Gale Group

Return to Candesartan
Home Contact Resources Exchange Links ebay